Literature DB >> 17360943

Lipoprotein metabolism and lipid management in chronic kidney disease.

Bonnie C H Kwan1, Florian Kronenberg, Srinivasan Beddhu, Alfred K Cheung.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17360943     DOI： 10.1681/ASN.2006091006

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  93 in total

Review 1.  Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.

Authors:  Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-06-22       Impact factor: 2.801

Review 2.  PCSK9 in chronic kidney disease.

Authors:  P Pavlakou; E Liberopoulos; E Dounousi; M Elisaf
Journal:  Int Urol Nephrol       Date:  2017-01-13       Impact factor: 2.370

3.  Serum amyloid A in uremic HDL promotes inflammation.

Authors:  Thomas Weichhart; Chantal Kopecky; Markus Kubicek; Michael Haidinger; Dominik Döller; Karl Katholnig; Cacang Suarna; Philipp Eller; Markus Tölle; Christopher Gerner; Gerhard J Zlabinger; Markus van der Giet; Walter H Hörl; Roland Stocker; Marcus D Säemann
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

Review 4.  Unfractionated heparin for hemodialysis: still the best option.

Authors:  Robert E Cronin; Robert F Reilly
Journal:  Semin Dial       Date:  2010 Sep-Oct       Impact factor: 3.455

Review 5.  Causes and consequences of lipoprotein(a) abnormalities in kidney disease.

Authors:  Florian Kronenberg
Journal:  Clin Exp Nephrol       Date:  2013-10-16       Impact factor: 2.801

Review 6.  Dyslipidemia in patients with chronic and end-stage kidney disease.

Authors:  Jad Omran; Ashraf Al-Dadah; Kevin C Dellsperger
Journal:  Cardiorenal Med       Date:  2013-07-13       Impact factor: 2.041

7.  Longitudinal lipid trends and adverse outcomes in patients with CKD: a 13-year observational cohort study.

Authors:  Ching-Wei Tsai; Han-Chun Huang; Hsiu-Yin Chiang; Chih-Wei Chung; Shih-Ni Chang; Pei-Lun Chu; Chin-Chi Kuo
Journal:  J Lipid Res       Date:  2019-01-14       Impact factor: 5.922

8.  Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.

Authors:  Mario Cozzolino; Maria Antonietta Rizzo; Andrea Stucchi; Daniele Cusi; Maurizio Gallieni
Journal:  Ther Adv Chronic Dis       Date:  2012-03       Impact factor: 5.091

9.  Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23.

Authors:  John R Montford; Michel Chonchol; Alfred K Cheung; James S Kaufman; Tom Greene; William L Roberts; Gerard Smits; Jessica Kendrick
Journal:  Am J Nephrol       Date:  2013-02-20       Impact factor: 3.754

10.  A prospective controlled study of kidney donors: baseline and 6-month follow-up.

Authors:  Bertram L Kasiske; Teresa Anderson-Haag; Hassan N Ibrahim; Todd E Pesavento; Matthew R Weir; Joseph M Nogueira; Fernando G Cosio; Edward S Kraus; Hamid H Rabb; Roberto S Kalil; Andrew A Posselt; Paul L Kimmel; Michael W Steffes
Journal:  Am J Kidney Dis       Date:  2013-03-22       Impact factor: 8.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.